Autres langues

14/12/23 Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index
11/12/23 Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index
11/12/23 Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index
21/11/23 Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023
21/11/23 Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer
21/11/23 Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023
09/11/23 Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
17/10/23 Top Midday Decliners
17/10/23 Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell
17/10/23 Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
17/10/23 Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
10/10/23 Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer
14/08/23 Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
14/08/23 Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
21/07/23 Evelo Biosciences Signs Termination Agreement for Cambridge Office, Laboratory Space; Shares Up Premarket
12/07/23 Evelo Biosciences Secures $25.5 Million in Private Placement
12/07/23 Evelo Biosciences Closes $25.5 Million Private Placement
11/07/23 Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering
10/07/23 Evelo Biosciences Enters Deal for $25.5 Million Private Placement of Common Shares
10/07/23 Evelo Biosciences, Inc. Announces Management Changes
10/07/23 Evelo Biosciences Announces $25.5 Million Private Placement
07/07/23 Evelo Biosciences, Inc. announced that it expects to receive $25.468522 million in funding from FMR LLC, Flagship Pioneering
29/06/23 Evelo Biosciences to Implement 1-for-20 Reverse Stock Split
29/06/23 Evelo Biosciences Announces Reverse Stock Split Effective
29/06/23 Evelo Biosciences Announces Reverse Stock Split Effective
Aucun résultat pour cette recherche